{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:44Z","timestamp":1793225984907,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00262-020-02600-0","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T07:05:30Z","timestamp":1589526330000},"page":"2033-2039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-0599","authenticated-orcid":false,"given":"Hirofumi","family":"Utsumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Araya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takekoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Minagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"2600_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2147\/CMAR.S136818","volume":"9","author":"S Chuzi","year":"2017","unstructured":"Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, Giles FJ (2017) Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 9:207\u2013213","journal-title":"Cancer Manag Res"},{"key":"2600_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V (2017) Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 152:271\u2013281","journal-title":"Chest"},{"key":"2600_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168","journal-title":"N Engl J Med"},{"key":"2600_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2:1346\u20131353","journal-title":"JAMA Oncol"},{"key":"2600_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"key":"2600_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3:1185\u20131192","journal-title":"Cancer Immunol Res"},{"key":"2600_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.ejrad.2015.03.017","volume":"84","author":"M Nishino","year":"2015","unstructured":"Nishino M, Tirumani SH, Ramaiya NH, Hodi FS (2015) Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol 84:1259\u20131268","journal-title":"Eur J Radiol"},{"key":"2600_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2016","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon R-A, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD (2016) Pneumonitis in patients treated with anti\u2013programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35:709\u2013717","journal-title":"J Clin Oncol"},{"key":"2600_CR9","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","volume":"22","author":"M Nishino","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Stephen Hodi F (2016) PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22:6051\u20136060","journal-title":"Clin Cancer Res"},{"key":"2600_CR10","doi-asserted-by":"publisher","first-page":"1701319","DOI":"10.1183\/13993003.01319-2017","volume":"50","author":"D Montani","year":"2017","unstructured":"Montani D, Seferian A, Parent F, Humbert M (2017) Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues. Eur Respir J 50:1701319","journal-title":"Eur Respir J"},{"key":"2600_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJMc1505197","volume":"373","author":"M Nishino","year":"2015","unstructured":"Nishino M, Sholl LM, Stephen Hodi F (2015) Anti\u2013PD-1\u2013related pneumonitis during cancer immunotherapy. N Engl J Med 373:288\u2013290","journal-title":"N Engl J Med"},{"key":"2600_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0961203314554849","volume":"24","author":"T Kurita","year":"2015","unstructured":"Kurita T, Yasuda S, Amengual O, Atsumi T (2015) The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis\/dermatomyositis. Lupus 24:3\u20139","journal-title":"Lupus"},{"key":"2600_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.2169\/internalmedicine.39.428","volume":"39","author":"F Tanaka","year":"2000","unstructured":"Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A, Kawabe Y, Eguchi K (2000) Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med 39:428\u2013430","journal-title":"Intern Med"},{"key":"2600_CR14","first-page":"1719","volume":"32","author":"H Kameda","year":"2005","unstructured":"Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T (2005) Combination therapy with corticosteroids, cyclosporine A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32:1719\u20131726","journal-title":"J Rheumatol"},{"key":"2600_CR15","unstructured":"Cancer Therapy Evaluation Program, National Cancer Institute (2009) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. (v4.03: 14 Jun 2010). https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed 28 May 2009"},{"key":"2600_CR16","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2:1607\u20131616","journal-title":"JAMA Oncol"},{"key":"2600_CR17","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, P\u00e9rol M, Campana M, Gautschi O, Fr\u00fch M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Pr\u00e9vot G, Milia J, Mazieres J (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50:1700050","journal-title":"Eur Respir J"},{"key":"2600_CR18","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","volume":"13","author":"K Suresh","year":"2018","unstructured":"Suresh K, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, D'Alessio F, Hales RK, Lin CT, Psoter KJ, Danoff SK, Naidoo J (2018) Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol 13:1930\u20131939","journal-title":"J Thorac Oncol"},{"key":"2600_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","volume":"125","author":"JY Cho","year":"2018","unstructured":"Cho JY, Kim J, Lee JS, Kim YJ, Kim SH, Lee YJ, Cho YJ, Yoon HI, Lee JH, Lee CT, Park JS (2018) Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer 125:150\u2013156","journal-title":"Lung Cancer"},{"key":"2600_CR20","doi-asserted-by":"publisher","first-page":"190058","DOI":"10.1183\/16000617.0058-2019","volume":"28","author":"J Cadranel","year":"2019","unstructured":"Cadranel J, Canellas A, Matton L, Darrason M, Parrot A, Naccache JM, Lavol\u00e9 A, Ruppert AM, Fallet V (2019) Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. Eur Respir Rev 28:190058","journal-title":"Eur Respir Rev"},{"key":"2600_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-018-0400-4","volume":"6","author":"GO Sanchez","year":"2018","unstructured":"Sanchez GO, Jahn K, Savic S, Zippelius A, L\u00e4ubli H (2018) Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. J Immunother Cancer 6:85","journal-title":"J Immunother Cancer"},{"key":"2600_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1378\/chest.08-2740","volume":"136","author":"H Mukae","year":"2009","unstructured":"Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, Ishimatsu Y, Kawakami A, Eguchi K, Kohno S (2009) Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136:1341\u20131347","journal-title":"Chest"},{"key":"2600_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40064-015-1013-8","volume":"4","author":"S Ikeda","year":"2015","unstructured":"Ikeda S, Arita M, Misaki K, Mishima S, Takaiwa T, Nishiyama A, Ito A, Furuta K, Yokoyama T, Tokioka F, Noyama M, Yoshioka H, Ishida T (2015) Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. Springerplus 4:240","journal-title":"Springerplus"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02600-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T19:16:53Z","timestamp":1621019813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02600-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"5 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient for publication of this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}